1,159 Followers on Owler

Kite Pharma

Kite Pharma is a biotechnology company that discovers and develops cell-based immunotherapies for the treatment of cancer. Read more

Christi L. Shaw's photo - CEO of Kite Pharma

CEO

Christi L. Shaw

CEO Approval Rating

81/100

KITE PHARMA TOP COMPETITORS OR ALTERNATIVES

RANK

COMPANY

CEO

CEO RATING

EMPLOYEES

FUNDING

REVENUE

Missing a competitor? Contribute!

Jounce is perceived as one of Kite Pharma's biggest rivals. Jounce is headquartered in Cambridge, Massachusetts, and was founded in 2012. Like Kite Pharma, Jounce also operates in the Biotechnology industry. Jounce generates 332% the revenue of Kite Pharma.

Agenus is one of Kite Pharma's top competitors. Agenus is a Public company that was founded in 1994 in Lexington, Massachusetts. Like Kite Pharma, Agenus also operates in the Biotechnology field. Compared to Kite Pharma, Agenus has 1,641 fewer employees.

bluebird bio has been one of Kite Pharma's top competitors. bluebird bio was founded in 1992 in Cambridge, Massachusetts. Like Kite Pharma, bluebird bio also works within the Biotechnology field. bluebird bio generates $196.7M more revenue than Kite Pharma.

Weigh-in!

Help the Owler community know more

Growth Score - 1/1

Is $45M a good estimate for Kite Pharma's revenue?

Kite Pharma Acquisitions

No recent acquisitions found related to Kite Pharma

Kite Pharma Funding History

Since Kite Pharma was founded in 2009, it has participated in 6 rounds of funding. In total Kite Pharma has raised $634.9M. Kite Pharma's last funding round was on Mar 2017 for a total of $409.7M

ROUND

FUNDING DATE

AMOUNT

INVESTORS

Post-IPO Equity
Mar 2017
$409.7M
-
IPO
Jun 2014
$127.5M
-
Debt
Apr 2014
$50M
Series A
May 2013
$35M
Debt
Nov 2012
$250K

Since Kite Pharma was founded in 2009, it has participated in 6 rounds of funding. In total Kite Pharma has raised $634.9M. Kite Pharma's last funding round was on Mar 2017 for a total of $409.7M

Kite Pharma Investments

COMPANY

DESCRIPTION

AMOUNT

INVESTMENT DATE

ROUND

EXIT DATE

Shoreline is a California-based biotechnology company that researches and develops cell-based immunotherapies for the treatment of cancer and orphan diseases.
$43M
Apr 06, 2021
Venture Round
-
Orna Therapeutics is a biotechnology company that develops engineered circular RNA therapeutics to treat cancer, autoimmune and genetic disorders.
$80M
Feb 23, 2021
Series A
-
Vineti develops a personalized therapy management platform that aligns and manages production processes for cell and gene therapies.
$68M
Feb 04, 2020
Series C
-
HiFiBiO is a Massachusetts-based biotherapeutics company that discovers, develops and commercializes antibody drugs for the treatment of cancer and autoimmune diseases.
$67M
Aug 28, 2019
Series C
-
Gadeta develops immunotherapies for the treatment of cancerous hematological disorders.
-
Jul 24, 2018
Equity
-

Kite Pharma News

April 3, 2021Pharmabiz

Kite seeks US FDA approval for Tecartus to treat adult patients with relapsed or refractory AML

Kite, a Gilead Company announced that it has submitted a supplemental Biologics License Application (... See more »
March 29, 2021Los Angeles Business Journal

Kite Pharma's Yescarta Approved for Adult Lymphoma Treatment

Santa Monica-based Kite Pharma announced March 5 that the Food and Drug Administration has granted ac... See more »
March 16, 2021BioSpace

COTA, Inc. and Kite Collaborate To Expand the Use of Real-World Data To Drive Faster, Effective Treatments for Cancers

COTA, Inc., an oncology real-world data and analytics company, today announced a collaboration with K... See more »
March 8, 2021Benzinga

Gilead's Kite Pharma Earns FDA Nod For Yescarta For Type Of Blood Cancer

The FDA has granted accelerated approval to Gilead Sciences Inc's (NASDAQ: GILD) Kite Pharma's 'Yesca... See more »
March 8, 2021Drug Store News

Kite wins FDA OK for new indication for Yescarta

Kite's Yescarta is the first CAR T-Cell therapy approved for indolent follicular lymphoma.... See more »
February 24, 2021FinSMEs

Orna Therapeutics Raises Over $100M Funding

Orna Therapeutics, a Cambridge, Mass.-based biotechnology company dedicated to designing and deliveri... See more »
February 10, 2021MarketScreener

Kite Announces New ZUMA-1 Cohort Analysis Evaluating Prophylactic Corticosteroid Use With Yescarta in Patients With Relapsed or Refractory Large B-cell lymphoma

(marketscreener.com) -- Use of Corticosteroids Prior to Yescarta Infusion Has the Potential to Impact... See more »

Kite Pharma Press Releases

December 6, 2020StreetInsider

Yescarta Shows Positive Results as a First-Line Treatment for Patients With High-Risk Large B-cell Lymphoma

-- 85 Percent of Patients Responded to a Single Infusion of Yescarta, Including 74 Percent of Patient... See more »
December 5, 2020StreetInsider

New Data for TecartusTM Demonstrate Durable Responses at One Year Follow-Up in Relapsed or Refractory Mantle Cell Lymphoma

-- Median Overall Survival Still Not Reached After Single Infusion of Tecartus in Pivotal ZUMA-2 Tria... See more »
November 5, 2020Business Wire

Gilead and Kite to Share Latest Scientific Advances in Hematologic Malignancies at ASH 2020

FOSTER CITY, Calif. & SANTA MONICA, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) and... See more »
October 30, 2020PR Newswire

Amarna Therapeutics Appoints Kite Pharma veteran Dr. Markwin Velders to its Supervisory Board

LEIDEN, Netherlands, Oct. 30, 2020 /PRNewswire/ -- Amarna Therapeutics, a Dutch privately held biotec... See more »
September 30, 2020PRWeb

Kite Pharma, Inc. Wins 2020 MEDA Economic Development Project Award

Kite Pharma, Inc., a Gilead Company, has been named by the Maryland Economic Development Association ... See more »
September 4, 2020centralcharts

Kite Submits Supplemental Biologics License Application to U.S. Food and Drug Administration for Yescarta in Relapsed or Refractory Indolent Non-Hodgkin Lymphomas

Kite, a Gilead Company (Nasdaq: GILD), today announced that it has submitted a supplemental Biologics... See more »
October 23, 2019centralcharts

Humanigen updates on its clinical collaboration with Gilead Sciences subsidiary, Kite

Humanigen Inc (OTCMKTS:HGEN) CEO Cameron Durrant spoke with Proactive at the 2019 BIO Investor Forum ... See more »

Social Media

Kite Pharma Headquarters

2400 Broadway

Santa Monica, California90404

310-824-9999

Driving Directions »

Trending Companies

Kite Pharma Summary

ABOUT

Overview

Kite Pharma is a biotechnology company that discovers and develops cell-based immunotherapies for the treatment of cancer. Kite Pharma was founded in 2009. Kite Pharma's headquarters is located in Santa Monica, California, USA 90404. It has raised 634...

CEO

Kite Pharma's CEO, Christi L. Shaw, currently has an approval rating of 81%. Kite Pharma's primary competitors are Jounce, Agenus & bluebird bio.

Frequently Asked Questions about Kite Pharma

  1. When was Kite Pharma founded?

    Kite Pharma was founded in 2009
  2. Who is Kite Pharma's CEO?

    Kite Pharma's CEO is Christi L. Shaw
  3. How much revenue does Kite Pharma generate?

    Kite Pharma generates $45M in revenue
  4. How much funding does Kite Pharma have?

    Kite Pharma has historically raised $634.9M in funding
  5. Where is Kite Pharma's headquarters?

    Kite Pharma's headquarters is in Santa Monica California, USA
  1. How many employees does Kite Pharma have?

    Kite Pharma has 2,000 employees
  2. What sector does Kite Pharma operate in?

    Kite Pharma is in Biotechnology, Pharmaceuticals
  3. Who are Kite Pharma's competitors?

    Kite Pharma's top competitors are Jounce, Agenus, bluebird bio
  4. Who has Kite Pharma invested in?

    Kite Pharma's has invested in companies such as Shoreline, Orna Therapeutics, Vineti